Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Albany Molecular Research (NasdaqNM:AMRI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 20Price hit new 52-week low ($23.29)
Aug  7Earnings Announcement
Location
21 Corporate Circle, PO Box 15098
Albany, NY 12212
Phone: (518) 464-0279
Fax: (518) 464-0257
Email: investorinfo@albmolecular.com
Employees (last reported count): 379
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 38%
·Over the last 6 months:
 · 6 insider sells; 37.0K shares
  (0.3% of insider shares)
·Institutional: 49% (80% of float)
(254 institutions)
·Net Inst. Selling: 1.82M shares (+12.54%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Albany Molecular Research, Inc. is a drug discovery and development company focused on applications for the pharmaceutical, biotechnology and life sciences industries. The Company engages in chemistry research, including lead discovery, optimization, development and commercial manufacturing. The Company performs chemistry research for many leading pharmaceutical and biotechnology companies and for its own internal research and development. In addition to its chemistry research services, the Company also conducts proprietary research and development to discover new lead compounds with commercial potential. The Company's analytical chemistry services include identity and purity testing, method development and validation, and stability testing.
More from Market Guide: Expanded Business Description

Financial Summary
Albany Molecular Research is a drug discovery and development company focused on applications for the pharmaceutical, biotechnology and life sciences industries. For the six months ended 6/30/01, revenues rose 51% to $45.4 million. Net income rose 62% to $16.7 million. Revenues reflect increased medicinal and chemical development services contracts and the addition of ten new customers. Net income also reflects improved contract rates and increased other income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Thomas D' Ambra, Ph.D., 45
Chairman and CEO
$3.2M--  
Donald Kuhla, Ph.D., 58
Pres, ChiefOperating Officer
295K$694K
David Waldek, 36
CFO and Treasurer
234K--  
Lawrence Jones, Ph.D., 49
Sr. VP, Bus. Devel.
191K--  
Michael Trova, Ph.D., 39
Sr. VP, Medicinal Chemistry
194K705K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AMRIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Aug-2001
$23.29 
Recent Price$26.02 
52-Week High
on 27-Dec-2000
$71.00 
Beta0.20 
Daily Volume (3-month avg)304.4K
Daily Volume (10-day avg)290.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-27.8%
52-Week Change
relative to S&P500
-3.2%
Share-Related Items
Market Capitalization$861.6M
Shares Outstanding33.1M
Float20.5M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 25-Aug-2000
Per-Share Data
Book Value (mrq)$7.45 
Earnings (ttm)$0.89 
Earnings (mrq)$0.26 
Sales (ttm)$2.43 
Cash (mrq)$4.32 
Valuation Ratios
Price/Book (mrq)3.49 
Price/Earnings (ttm)29.34 
Price/Sales (ttm)10.70 
Income Statements
Sales (ttm)$81.9M
EBITDA (ttm)$43.2M
Income available to common (ttm)$30.0M
Profitability
Profit Margin (ttm)36.6%
Operating Margin (ttm)48.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)15.44%
Return on Equity (ttm)16.46%
Financial Strength
Current Ratio (mrq)10.02 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$142.8M
Short Interest
As of 8-Aug-2001
Shares Short789.0K
Percent of Float3.8%
Shares Short
(Prior Month)
772.0K
Short Ratio2.36 
Daily Volume334.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.